Telix Pharmaceuticals Limited Stock Performance
| TLX Stock | 14.70 0.07 0.47% |
The entity has a beta of -0.072, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Telix Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Telix Pharmaceuticals is likely to outperform the market. At this point, Telix Pharmaceuticals has a negative expected return of -0.42%. Please make sure to validate Telix Pharmaceuticals' jensen alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Telix Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Telix Pharmaceuticals Limited has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 0.81 | Year To Date Return (1.65) | Ten Year Return (21.58) | All Time Return (50.33) |
Last Split Factor 1:1000 | Last Split Date 2013-10-29 |
| Begin Period Cash Flow | 116.3 M | |
| Free Cash Flow | -10.8 M |
Telix |
Telix Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,515 in Telix Pharmaceuticals Limited on August 25, 2024 and sell it today you would lose (45.00) from holding Telix Pharmaceuticals Limited or give up 2.97% of portfolio value over 90 days. Telix Pharmaceuticals Limited is generating negative expected returns assuming volatility of 1.6896% on return distribution over 90 days investment horizon. In other words, 15% of stocks are less volatile than Telix, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Telix Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Telix Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Telix Pharmaceuticals Limited, and traders can use it to determine the average amount a Telix Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2472
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TLX |
Estimated Market Risk
| 1.69 actual daily | 15 85% of assets are more volatile |
Expected Return
| -0.42 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.25 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Telix Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Telix Pharmaceuticals by adding Telix Pharmaceuticals to a well-diversified portfolio.
Telix Pharmaceuticals Fundamentals Growth
Telix Stock prices reflect investors' perceptions of the future prospects and financial health of Telix Pharmaceuticals, and Telix Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Telix Stock performance.
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0797 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 4.77 B | ||||
| Shares Outstanding | 334.13 M | ||||
| Price To Book | 18.79 X | ||||
| Price To Sales | 7.64 X | ||||
| Revenue | 496.66 M | ||||
| EBITDA | 23.77 M | ||||
| Total Debt | 17.45 M | ||||
| Book Value Per Share | 1.21 X | ||||
| Earnings Per Share | 0.10 X | ||||
| Market Capitalization | 4.93 B | ||||
| Total Asset | 398.3 M | ||||
| Retained Earnings | (263.67 M) | ||||
About Telix Pharmaceuticals Performance
Evaluating Telix Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Telix Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Telix Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 33.58 | 67.13 | |
| Return On Tangible Assets | 0.02 | 0.02 | |
| Return On Capital Employed | 0.07 | 0.07 | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.03 | 0.04 |
Things to note about Telix Pharmaceuticals performance evaluation
Checking the ongoing alerts about Telix Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Telix Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Telix Pharmaceuticals generated a negative expected return over the last 90 days | |
| Latest headline from finance.yahoo.com: 3 Stocks That May Be Undervalued By Up To 43.6 percent Based On Intrinsic Estimates |
- Analyzing Telix Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Telix Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Telix Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Telix Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Telix Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Telix Pharmaceuticals' stock. These opinions can provide insight into Telix Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.